Bimekizumab 4-Year Maintenance of Responses in Week 16 Responders With Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-Label Extension Phase 3 Trial. J of Skin 2024, 8 (6), s437. https://doi.org/10.25251/skin.8.supp.437.